InnoCare Pharma Doses First Patient in Global Phase II Trial of TYK2 Inhibitor Soficitinib for Prurigo Nodularis

Reuters11-28

InnoCare Pharma Doses First Patient in Global Phase II Trial of TYK2 Inhibitor Soficitinib for Prurigo Nodularis

InnoCare Pharma Ltd. has announced the dosing of the first patient in a global Phase II clinical trial of its TYK2 inhibitor, Soficitinib (ICP-332), for the treatment of prurigo nodularis in China. Soficitinib is being developed for several T-cell related autoimmune disorders, with a focus on dermatological conditions such as atopic dermatitis, vitiligo, prurigo nodularis, and urticaria. The company previously presented data from a Phase II clinical study of Soficitinib for moderate-to-severe atopic dermatitis, demonstrating efficacy and a strong safety profile, at the American Academy of Dermatology (AAD) Annual Meeting. The prurigo nodularis market was valued at US$2 billion in 2024 and is projected to reach US$3 billion by 2034.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9593554-en) on November 28, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2586227107?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-28 09:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2586227107","market":"us","top_or_hot":-1,"title":"InnoCare Pharma Doses First Patient in Global Phase II Trial of TYK2 Inhibitor Soficitinib for Prurigo Nodularis","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      InnoCare Pharma Doses First Patient in Global Phase II Trial of TYK2 Inhibitor Soficitinib for Prurigo Nodularis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        InnoCare Pharma Ltd. has announced the dosing of the first patient in a global Phase II clinical trial of its TYK2 inhibitor, Soficitinib (ICP-332), for the treatment of prurigo nodularis in China. Soficitinib is being developed for several T-cell related autoimmune disorders, with a focus on dermatological conditions such as atopic dermatitis, vitiligo, prurigo nodularis, and urticaria. The company previously presented data from a Phase II clinical study of Soficitinib for moderate-to-severe atopic dermatitis, demonstrating efficacy and a strong safety profile, at the American Academy of Dermatology (AAD) Annual Meeting. The prurigo nodularis market was valued at US$2 billion in 2024 and is projected to reach US$3 billion by 2034.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9593554-en) on November 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>InnoCare Pharma Doses First Patient in Global Phase II Trial of TYK2 Inhibitor Soficitinib for Prurigo Nodularis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnoCare Pharma Doses First Patient in Global Phase II Trial of TYK2 Inhibitor Soficitinib for Prurigo Nodularis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-28 09:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      InnoCare Pharma Doses First Patient in Global Phase II Trial of TYK2 Inhibitor Soficitinib for Prurigo Nodularis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        InnoCare Pharma Ltd. has announced the dosing of the first patient in a global Phase II clinical trial of its TYK2 inhibitor, Soficitinib (ICP-332), for the treatment of prurigo nodularis in China. Soficitinib is being developed for several T-cell related autoimmune disorders, with a focus on dermatological conditions such as atopic dermatitis, vitiligo, prurigo nodularis, and urticaria. The company previously presented data from a Phase II clinical study of Soficitinib for moderate-to-severe atopic dermatitis, demonstrating efficacy and a strong safety profile, at the American Academy of Dermatology (AAD) Annual Meeting. The prurigo nodularis market was valued at US$2 billion in 2024 and is projected to reach US$3 billion by 2034.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9593554-en) on November 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0314104364.USD","symbol_name":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nNDL34LJDg:1","article_id":"2586227107","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2586227107","pubTimestamp":1764294935,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"InnoCare Pharma Ltd. has announced the dosing of the first patient in a global Phase II clinical trial of its TYK2 inhibitor, Soficitinib , for the treatment of prurigo nodularis in China. Soficitinib is being developed for several T-cell related autoimmune disorders, with a focus on dermatological conditions such as atopic dermatitis, vitiligo, prurigo nodularis, and urticaria. The company previously presented data from a Phase II clinical study of Soficitinib for moderate-to-severe atopic dermatitis, demonstrating efficacy and a strong safety profile, at the American Academy of Dermatology  Annual Meeting. The prurigo nodularis market was valued at US$2 billion in 2024 and is projected to reach US$3 billion by 2034.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial,","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688428":"诺诚健华","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4585":"ETF&股票定投概念","NDAQ":"纳斯达克OMX交易所","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK0239":"医药制造","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4588":"碎股","BK4112":"金融交易所和数据","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H"},"translate_title":"诺诚健华医药TYK2抑制剂索非替尼治疗结节性痒疹全球II期试验首例患者给药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688428":0.9,"NDAQ":0.9},"content_text":"InnoCare Pharma Doses First Patient in Global Phase II Trial of TYK2 Inhibitor Soficitinib for Prurigo Nodularis\n    \n\n        InnoCare Pharma Ltd. has announced the dosing of the first patient in a global Phase II clinical trial of its TYK2 inhibitor, Soficitinib (ICP-332), for the treatment of prurigo nodularis in China. Soficitinib is being developed for several T-cell related autoimmune disorders, with a focus on dermatological conditions such as atopic dermatitis, vitiligo, prurigo nodularis, and urticaria. The company previously presented data from a Phase II clinical study of Soficitinib for moderate-to-severe atopic dermatitis, demonstrating efficacy and a strong safety profile, at the American Academy of Dermatology (AAD) Annual Meeting. The prurigo nodularis market was valued at US$2 billion in 2024 and is projected to reach US$3 billion by 2034.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9593554-en) on November 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2586227107","isCrawlerRequest":true}